Benefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma.

Abstract

This is the first report of pediatric linear scleroderma successfully treated with the topical Janus kinase (JAK) inhibitor delgocitinib. JAK inhibitors targeting the JAK/STAT pathway have been used to treat various immune-mediated diseases. In both in vitro and in vivo, JAK inhibitors also block the transforming growth factor (TGF)-β-mediated effects that contribute to skin sclerosis. In the present case, the histological findings of inflammation and fibrosis were considered as conditions that would benefit from the anti-inflammatory and antifibrotic effects of the JAK inhibitor, delgocitinib.